A crossover study of risperidone in children, adolescents and adults with mental retardation

Journal of Autism and Developmental Disorders

Volumn 36, Issue 3, 2006, Pages 401-411

  Hellings, Jessica A ^a,d   Zarcone, Jennifer R ^a   Reese, R Matthew ^a   Valdovinos, Maria G ^b   Marquis, Janet G ^c   Fleming, Kandace K ^c   Schroeder, Stephen R ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Mental retardation; Risperidone; Weight gain

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGGRESSION; APPETITE DISORDER; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MOOD DISORDER; MULTICENTER STUDY; MUSCLE STIFFNESS; NOSE CONGESTION; PRIORITY JOURNAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SEDATION; SEX ROLE; SIDE EFFECT; TREATMENT DURATION; TREMOR; URINE INCONTINENCE; URINE RETENTION; WEIGHT CONTROL; WEIGHT GAIN;

ADOLESCENT; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; RISPERIDONE; WEIGHT GAIN;

EID: 33744828978     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-006-0078-1     Document Type: Article

References (29)

1. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.
2. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., & Findling, R. L. (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behavior disorders in children with subaverage intelligence. American Journal Psychiatry, 159, 1337-1346.
3. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association.
4. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journalof Autism and Developmental Disorders, 19, 227-239.
5. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 41, 1195-1202.
6. Breese, G. R. (2002). Age-dependent reduction of brain dopamine: Relationship to self-injurious behavior. In: S. R. Schroeder, M. L. Oster-Granite, & T. Thompson (Eds.), Self-injurious behavior: Gene-brain-behavior relationships. (pp. 279-287). Washington, DC: American Psychological Association.
7. Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 835-843.
8. Cook, E. H., & Leventhal, B. L. (1996). The serotonin system in autism. Current Opinions in Pediatrics, 8, 348-354.
9. Cook, E. H. Jr., Courchesne, R., Lord, C., Cox, N. J., Yan, S., & Lincoln, A. (1997). Evidence of linkage between the serotonin transporter and autistic disorder. Molecular Psychiatry, 2, 247-250.
10. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
11. Gualtieri, C. T. (1984). The Neuroleptic Side Effects Checklist. Unpublished Scale available from the author.
12. Guy, W. (1976). Assessment manual for psychopharmacology. Washington, DC: U.S. Government Printing Office.
13. Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229-238.
14. Hellings, J. A., Zarcone, J. R., Valdovinos, M. G., Reese, R. M., Gaughan, E., & Schroeder, S. R. (2005). Risperidone-induced prolactin elevation in a study of children, adolescents and adults with mental retardation and pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15, 885-892.
15. Kawachi, I. (1999). Health consequences of weight gain. In: Therapeutic advances in psychoses: Weight gain associated with use of psychotropic drugs. Belle Mead, NJ: Excerpta Medica, Inc 1-3.
16. Kim, S. J., Cox, N., Courcheshe, R., Lord, C., Corsello, C., Ashoomoff, N. et al. (2002). Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. Molecular Psychiatry, 7, 278-288.
17. Leiter, R. G. (1948). Leiter international performance scale. Chicago. IL: Stoelting Co.
18. McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55, 633-641.
19. McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
20. Meltzer, H. Y. (1995). The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. Journal of Clinical Psychopharmacol, 15, 2S-3S.
21. Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
22. Schroeder, S. R., Rojahn, J., & Reese, R. M. (1997). Brief report: Reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. Journal of Autism and Developmental Disorders, 27, 89-102.
23. Siegel, S., & Castellan, N. J. Jr. (1988). Nonparametric statistics for the behavioral sciences (2nd ed.). New York: McGraw-Hill.
24. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A., & The Risperidone Conduct Study Group (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQ's. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026-1036.
25. Sprague, R. L., Kalachnik, J. E., & Shaw, K. M. (1989). Psychometric properties of the dyskinesia identification system: Condensed user scale (DISCUS). Mental Retardation, 27, 141-148.
26. Vitiello, B. (2002). Assessment of adverse events and preservation of blindness in clinical trials. Oral presentation at the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton, FL.
27. Wechsler, D. (1981). Manual for the Welchster adult intelligence scale-revised. San Antonio, Tex: Psychological Corp.
28. Wechsler, D. (1991). Manual for the Wechsler intelligence scale for children (3rd ed.). San Antonio, TX: Psychological Corp.
29. Zarcone, J. R., Hellings, J. A., Crandall, K., Reese, R. M., Marquis, J., Fleming, K. et al. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation, 106, 525-538.